It looks like you're using an Ad Blocker.
Please white-list or disable AboveTopSecret.com in your ad-blocking tool.
Thank you.
Some features of ATS will be disabled while you continue to use an ad-blocker.
originally posted by: infolurker
a reply to: Wisenox
Yep,
I would advise watching the video for details:
In April 2022, Pfizer shared top-line results from the Phase 2/3 EPIC-PEP (Evaluation of Protease Inhibition for COVID-19 in Post-Exposure Prophylaxis) study in adults living in the same household as someone with a confirmed COVID-19 infection observing a risk reduction of 32% and 37% in adults who received Paxlovid for five and ten days, respectively, to prevent infection. These results, however, were not statistically significant and, as such, the primary endpoint of reducing the risk of confirmed and symptomatic COVID-19 infection in adults who had been exposed to the virus through a household contact
was not met. For additional information on Paxlovid, please see the COVID-19 Pandemic section of this MD&A.
originally posted by: OccamsRazor04
a reply to: v1rtu0s0
Well if they made it up they sure didn't make up something that makes them look bad. So which is it? Is the information real, damning, and they look bad; or is it made up so they look great?
originally posted by: OccamsRazor04
a reply to: litterbaux
Well all that is saying is there is always a risk of harm with new products, and investors need to be aware.